Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Cancer Med
; 9(13): 4640-4647, 2020 07.
Article
in En
| MEDLINE
| ID: mdl-32378799
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Phenylurea Compounds
/
Pyridines
/
Carcinoma, Hepatocellular
/
Antibodies, Monoclonal, Humanized
/
Sorafenib
/
Anilides
/
Liver Neoplasms
/
Antineoplastic Agents
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
America do norte
Language:
En
Journal:
Cancer Med
Year:
2020
Document type:
Article
Affiliation country: